StockDrifts LogoStockDrifts

Keeps Pharma 256940

Company
킵스파마Keeps Pharma
Insiders
0
Buys
0
Total Value
Avg Return
Last Filing
2026-05-07

Keeps Pharma (256940) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Keeps Pharma is dated 2024-03-29; the most recent is 2026-05-07. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-05-07SELL임원퇴임
김정호
Kim Jeong-ho
president-248.4K₩7,260+9.1%₩1.8B ($1.3M)
2026-03-01BUY신규선임
김형규
Kim Hyeong-gyu
moving3.0K₩7,690+6.8%₩23M ($16K)
2024-11-01BUY신규선임
최정주
Jeongju Choi
Managing Director19.8K₩5,990+37.1%₩119M ($83K)
2024-03-29SELL임원퇴임
노관민
Noh Gwan-min
thanks-26.5K₩6,950-18.1%₩184M ($128K)

Frequently asked questions

Who has been buying Keeps Pharma stock?
0 distinct insiders have filed 0 disclosed insider purchases in Keeps Pharma (256940), most recently on 2026-05-07. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Keeps Pharma have?
Keeps Pharma has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-03-29 to 2026-05-07.
Where does StockDrifts get Keeps Pharma insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Keeps Pharma. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.